# US 2019/0376029 A1 · Methods of engineering human induced pluripotent stem cells to produce liver tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376029 A1
- Document ID: US20190376029A1
- Status: Published application
- Kind: A1
- Application number: 16/485,771
- Filed: 2018-02-13
- Published: 2019-12-12
- Earliest claimed: 2017-02-14
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education
- Inventors: Alejandro Soto-Gutierrez; Tomoji Mashimo; Alexandra Sylvie Collin de l'Hortet; Eduardo Cervantes Alvarez; Jorge Guzman Lepe; Kan Handa; Kazuki Takeishi; Yang Wang; Branimir Popovic
- Web page: https://patentgrep.com/patent/US20190376029A1

## CPC

- C12N 5/067: {Hepatocytes}
- A01K 67/027: New or modified breeds of vertebrates
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/10: Mammal
- A01K 2227/105: Murine
- A01K 2267/025: Animal producing cells or organs for transplantation
- C12N 2500/34: Sugars
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Methods are disclosed herein for producing human hepatocytes from human induced pluripotent stem cells. Also provided are transgenic rats for the expansion of human hepatocytes, such as those produced using the methods disclosed herein.

## Claims

### Claim 1

A method for producing human hepatocytes, comprising:
a) culturing human induced pluripotent stem cells (iPSC) in a first medium comprising an effective amount of activin A, fibroblast growth factor (FGF)-2 and bone morphogenic protein (BMP)-4 for about 2 to about 3 days, to produce mesendoderm cells;
b) culturing the mesendoderm cells in a second medium comprising an effective amount of activin A, and in absence of FGF-2 and BMP-4, for about 2 to about 3 days, to produce definitive endoderm cells;
c) culturing the definitive endoderm cells in a third medium comprising an effective amount of dimethyl sulfoxide (DMSO), and hepatocyte growth factor (HGF), wherein the third medium is a low glucose medium, for about eight to about 14 days, to produce hepatic-specified cells; and
d) culturing the hepatic-specified cells in a fourth medium comprising an effective amount of HGF, urso deoxycolic acid, cholesterol, palmitic acid, oleic acid, and rifampicin, wherein the fourth medium is a low glucose medium, and
thereby producing the human hepatocytes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first medium comprises about 50 to about 200 ng/ML of activin A, about 10 to about 50 ng/mL of FGF-2, and about 20 to about 100 ng/mL of BMP-4.

### Claim 3 (depends on 1)

The method of claim 1, wherein the second medium comprises about 50 to about 200 ng/mL of activin A.

### Claim 4 (depends on 3)

The method of claim 3, wherein the second medium further comprises an effective amount of L-glutamine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first medium and the second medium are replenished daily.

### Claim 6 (depends on 1)

The method of claim 1, wherein the third medium comprises about 1 to about 3 percent volume/volume (v/v) DMSO and about 20 to about 150 μg/mL of HGF.

### Claim 7 (depends on 6)

The method of claim 6, wherein the third medium further comprises about 0.5 to about 2% v/v L-glutamine.

### Claim 8 (depends on 1)

The method of claim 1, wherein the fourth medium comprises about 20 to about 150 μg/mL HGF, about 50 mM to about 150 mM urso deoxycolic acid, about 10 μM to about 50 μM palmitic acid, about 10 μM to about 50 μM about oleic acid, and about 10 μM to about 50 μM rifampicin.

### Claim 9 (depends on 8)

The method of claim 8, wherein the fourth medium further comprises an effective amount of L-glutamine, DMSO, and/or dexamethasone.

### Claim 10 (depends on 9)

The method of claim 9, wherein the fourth medium further comprises about 0.5 to about 2% v/v L-glutamine.

### Claim 11 (depends on 9)

The method of claim 9, wherein the fourth medium comprises about 1 to about 3% v/v DMSO.

### Claim 12 (depends on 9)

The method of claim 9, wherein the fourth medium comprises about 0.5 to about 2 mM dexamethasone.

### Claim 13 (depends on 1)

The method of claim 1, wherein the third medium and the fourth medium are replenished every other day.

### Claim 14 (depends on 1)

The method of claim 1, further comprising:
e) transplanting the hepatic-specified cells and/or the human hepatocytes into a liver of an immunocompromised non-human animal, thereby expanding the hepatic-specified cells and/or the human hepatocytes and producing human hepatocytes; and
f) harvesting the expanded hepatic-specified cells and/or the human hepatocytes.

### Claim 15 (depends on 14)

The method of claim 14, wherein the immunocompromised non-human animal is a transgenic rat.

### Claim 16 (depends on 15)

The method of claim 15, wherein the transgenic rat is a Rag2−/− Il2rg−/− rat harboring a transgene comprising a liver specific promoter, wherein the promoter is operably linked to a nucleic acid molecule encoding a fusion protein, and wherein the fusion protein comprises FKBP12 and caspase 9.

### Claim 17 (depends on 16)

The method of claim 16, wherein the promoter is an albumin promoter.

### Claim 18 (depends on 15)

The method of claim 15, wherein the hepatic-specified cells and/or the human hepatocytes are expanded in the transgenic rat for about 3 days to about 24 months.

### Claim 19 (depends on 14)

The method of claim 14, further comprising inhibiting growth of non-human hepatocytes of the immunocompromised non-human animal prior to transplanting the hepatic-specified cells and/or the human hepatocytes into the liver.

### Claim 20 (depends on 19)

The method of claim 19, wherein inhibiting growth of the non-human hepatocytes comprises administering an effective amount of radiation or retrorsine to the immunocompromised non-human animal.

### Claim 21 (depends on 14)

The method of claim 14, wherein about 0.5×106 to about 10×106 human hepatocytes are transplanted into the immunocompromised non-human transgenic animal.

### Claim 22

A method for producing human hepatocytes, comprising
a) culturing human induced pluripotent stem cells (iPSC) in a first medium comprising an effective amount of activin A, fibroblast growth factor (FGF)-2 and bone morphogenic protein (BMP)-4 for about 2 to about 3 days, to produce mesendoderm cells;
b) culturing the mesendoderm cells in a second medium comprising an effective amount of activin A, and in the absence of FGF-2 and BMP-4, for about 2 to about 3 days, to produce definitive endoderm cells;
c) culturing the definitive endoderm cells in a third medium comprising an effective amount of dimethyl sulfoxide (DMSO), and hepatocyte growth factor (HGF), wherein the third medium is a low glucose medium for about eight to about 14 days, to produce hepatic progenitor cells;
d) transplanting the hepatic progenitor cells into a liver of an immunocompromised non-human transgenic animal; and
e) harvesting human hepatocytes from the liver of the immunocompromised non-human transgenic animal.

### Claim 23 (depends on 22)

The method of claim 22, wherein the first medium comprises about 50 to about 200 ng/ML of activin A, about 10 to about 50 ng of FGF-2, and about 20 to about 100 ng/mL of BMP-4.

### Claim 24 (depends on 22)

The method of claim 22, wherein the second medium comprises about 50 to about 200 ng/mL of activin A.

### Claim 25 (depends on 24)

The method of claim 24, wherein the second medium further comprises an effective amount of L-glutamine.

### Claim 26 (depends on 22)

The method of claim 22, wherein the first medium and the second medium are replenished daily.

### Claim 27 (depends on 22)

The method of claim 22, wherein the third medium comprises about 1 to about 3 percent v/v DMSO and about 20 to about 150 μg/mL of HGF.

### Claim 28 (depends on 27)

The method of claim 27, wherein the third medium further comprises about 0.5 to about 2% v/v L-glutamine.

### Claim 29 (depends on 22)

The method of claim 22, wherein the third medium and the fourth medium are replenished every other day.

### Claim 30 (depends on 22)

The method of claim 22, wherein the immunocompromised non-human transgenic animal is a transgenic rat.

### Claim 31 (depends on 22)

The method of claim 22, further comprising inhibiting growth of non-human hepatocytes of the immunocompromised non-human transgenic animal prior to transplanting the hepatic progenitor cells into the liver of the immunocompromised non-human transgenic animal.

### Claim 32 (depends on 31)

The method of claim 31, wherein inhibiting growth of the non-human hepatocytes comprises administering an effective amount of radiation or retrorsine to the immunocompromised non-human transgenic animal.

### Claim 33 (depends on 30)

The method of claim 30, wherein the transgenic animal is a Rag2−/− Il2rg−/− rat harboring a transgene comprising a liver specific promoter operably linked to a nucleic acid molecule encoding a fusion protein, wherein the fusion protein comprises FKBP12 and caspase 9.

### Claim 34 (depends on 33)

The method of claim 33, wherein the liver specific promoter is an albumin promoter.

### Claim 35 (depends on 31)

The method of claim 31, wherein inhibiting the growth of the non-human hepatocytes comprises administering an effective amount of AP1903 or AP20187 to the immunocompromised non-human transgenic animal.

### Claim 36 (depends on 30)

The method of claim 30, wherein the hepatic progenitor cells are expanded in the transgenic rat for about 3 days to about 24 months.

### Claim 37 (depends on 14)

The method of claim 14, wherein about 0.5×106 to about 10×106 human hepatocytes are transplanted into the immunocompromised non-human transgenic animal.

### Claim 38 (depends on 22)

The method of claim 22, wherein the iPSC is transformed with a heterologous nucleic acid molecule operably linked to a promoter.

### Claim 39 (depends on 22)

The method of claim 22, wherein the human hepatocytes comprise a heterologous nucleic acid operably linked to a promoter.

### Claim 40 (depends on 39)

The method of claim 39, wherein the heterologous nucleic acid is a shRNA or encodes Cas9.

### Claim 41

A transgenic rat, wherein the transgenic rat is a Rag2−/−2rg−/− rat harboring a transgene comprising a liver specific promoter operably linked to a nucleic acid molecule encoding a fusion protein, wherein the fusion protein comprises FKBP12 and caspase 9, and wherein human hepatocytes can be expanded in a liver of the transgenic rat.

### Claim 42 (depends on 41)

The transgenic rat of claim 41, wherein the promoter is an albumin promoter or a transthyretin promoter.
